Is GHK-Cu FDA Approved? The Gene Expression Peptide's Regulatory Status

The Short Answer

Injectable GHK-Cu is not FDA-approved. No clinical trial has tested subcutaneous GHK-Cu for any indication. It is available as a compounded medication. However, GHK-Cu as a topical ingredient has been used in skincare products for over 40 years with an extensive safety record, and it is one of the most molecularly characterized peptides in existence thanks to the Broad Institute's genomic analysis.

What Is GHK-Cu?

GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide-copper complex first isolated from human blood plasma by Loren Pickart in 1973. Pickart discovered that old human plasma, when added to liver tissue from older donors, caused the tissue to synthesize proteins at the rate of young tissue. He traced the active factor to GHK-Cu.

GHK-Cu is endogenous — your body produces it. But plasma levels decline significantly with age: from approximately 200 ng/mL at age 20 to about 80 ng/mL by age 60. This decline correlates with reduced tissue regeneration, slower wound healing, thinner skin, and other hallmarks of aging.

The copper ion is essential to GHK-Cu's function. It is chelated (bound to the peptide), which allows safe transport into cells without causing oxidative damage. Inside cells, the copper participates in enzymatic reactions involved in collagen synthesis, elastin production, and antioxidant defense. GHK-Cu has been used safely in skincare for over 40 years with no reports of copper toxicity or allergic reactions.

The 4,000-Gene Discovery

In 2012, Pickart and colleagues used the Broad Institute's Connectivity Map (CMap) — a genomic database that maps how compounds affect gene expression — to analyze GHK's effects across the human genome. The results were striking: GHK modulates over 4,000 human genes, roughly 6% of the entire genome.

The gene expression changes fell into clear functional categories: 47 DNA repair genes stimulated (the largest cluster of DNA repair activation found for any tested compound), multiple cancer-related genes suppressed (including genes associated with metastasis and proliferation), collagen and extracellular matrix genes activated (driving tissue structural quality), and inflammatory genes downregulated (reducing chronic tissue inflammation).

This genomic analysis is why GHK-Cu is often called a "gene expression reprogramming" peptide. It does not target one pathway. It shifts the global gene expression profile of cells toward a pattern associated with younger, more regenerative tissue. The scale of this effect (4,000+ genes) is what sets GHK-Cu apart from other regenerative peptides.

Pickart L, Vasquez-Soltero JM, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International, 2015. View study

Topical vs Injectable: Why It Matters

GHK-Cu in skincare serums (available at Sephora, Amazon, and dermatology offices) delivers the peptide to the upper layers of the skin. It is effective for surface-level skin improvement: hydration, fine lines, and mild firming. But it cannot penetrate deep enough to reach the systemic connective tissue where the 4,000-gene effect would be most impactful.

Subcutaneous injectable GHK-Cu bypasses the skin barrier entirely. It enters systemic circulation and reaches fibroblasts, connective tissue, and organ systems throughout the body. The concentrations achieved are orders of magnitude higher than what topical application can deliver. This is the difference between applying lotion and actually replenishing what your body has lost.

Why No Clinical Trials for Injectable GHK-Cu

GHK-Cu is an endogenous tripeptide. It is the smallest peptide in the PeRx catalog. Small, naturally occurring molecules are nearly impossible to patent meaningfully. No pharmaceutical company will invest $1 billion in clinical trials for a molecule that compounding pharmacies can prepare the day after approval.

The topical skincare industry bypasses this problem entirely — cosmetics do not require FDA approval. But injectable medications must go through the full regulatory pathway, and the economics do not work for unpatentable molecules. This is the same barrier that affects BPC-157, DSIP, and most other naturally derived peptides.

Frequently Asked Questions